MannKind partners with Rose Pharma to develop inhaled GLP-1 treatment
MannKind (MNKD) is partnering with Rose Pharma to develop an inhaled weight-loss treatment using MannKind’s Technosphere platform, targeting the GLP-1 weight-loss market.
MannKind (MNKD) is moving into the GLP-1 weight-loss market through a partnership with Rose Pharma to develop an inhaled treatment using its proprietary Technosphere. The company is targeting a market that has been dominated by injectable GLP-1 therapies.